We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
- Authors
van den Bent, Martin; Azaro, Analia; De Vos, Filip; Sepulveda, Juan; Yung, W. K. Alfred; Wen, Patrick Y.; Lassman, Andrew B.; Joerger, Markus; Tabatabai, Ghazaleh; Rodon, Jordi; Tiedt, Ralph; Zhao, Sylvia; Kirsilae, Tiina; Cheng, Yi; Vicente, Sergio; Balbin, O. Alejandro; Zhang, Hefei; Wick, Wolfgang
- Abstract
Purpose: To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutation or protein loss. Methods: This multicenter, open-label, Phase Ib/II study included adult patients with glioblastoma with mesenchymal-epithelial transcription factor (c-Met) amplification. In Phase Ib, patients received INC280 as capsules or tablets in combination with buparlisib. In Phase II, patients received INC280 only. Response was assessed centrally using Response Assessment in Neuro-Oncology response criteria for high-grade gliomas. All adverse events (AEs) were recorded and graded. Results: 33 patients entered Phase Ib, 32 with altered PTEN. RP2D was not declared due to potential drug–drug interactions, which may have resulted in lack of efficacy; thus, Phase II, including 10 patients, was continued with INC280 monotherapy only. Best response was stable disease in 30% of patients. In the selected patient population, enrollment was halted due to limited activity with INC280 monotherapy. In Phase Ib, the most common treatment-related AEs were fatigue (36.4%), nausea (30.3%) and increased alanine aminotransferase (30.3%). MTD was identified at INC280 Tab 300 mg twice daily + buparlisib 80 mg once daily. In Phase II, the most common AEs were headache (40.0%), constipation (30.0%), fatigue (30.0%) and increased lipase (30.0%). Conclusion: The combination of INC280/buparlisib resulted in no clear activity in patients with recurrent PTEN-deficient glioblastoma. More stringent molecular selection strategies might produce better outcomes. Trial registration: NCT01870726.
- Subjects
PTEN protein; OLIGODENDROGLIOMAS; GLIOBLASTOMA multiforme; ALANINE aminotransferase; TRANSCRIPTION factors
- Publication
Journal of Neuro-Oncology, 2020, Vol 146, Issue 1, p79
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-019-03337-2